Prostate cancer screening: what can we learn from randomised trials?
نویسنده
چکیده
In this article, the principle of randomised trials are first described and then prostate cancer screening trials published to date are evaluated based on these principles. A summary of the randomised prostate cancer screening is provided. The conclusion that can be made from the results of the screening trials, as well as limitations of the evidence and open questions are outlined in the end.
منابع مشابه
What is the most appropriate test in detecting prostate cancer in patients with intermediate prostate specific antigen levels?
Abstract Background: Regarding the variety of tests present for detecting and also screening prostate cancer and also bearing in mind the advantages and disadvantages of these tests we decided to re-evaluate these tests (total prostate specific antigen and all of its modifications) in detecting prostate cancer in men with intermediate serum PSAlevels. Methods: Following a cross se...
متن کاملScreening for prostate cancer: systematic review and meta-analysis of randomised controlled trials
OBJECTIVE To examine the evidence on the benefits and harms of screening for prostate cancer. DESIGN Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES Electronic databases including Medline, Embase, CENTRAL, abstract proceedings, and reference lists up to July 2010. Review methods Included studies were randomised controlled trials comparing screening by prost...
متن کاملPSA Screening in Prostate Cancer
Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...
متن کاملProstate cancer screening in Europe.
1 Schröder FH, Hugoss on J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384: 2027–35. 2 Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013; 1: CD004720. 3 Djulbegovic M, Beyth RJ, Neuberger MM, et al. Scr...
متن کاملLatest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
The European Randomised Study of Screening for Prostate Cancer (ERSPC) demonstrated a significant reduction in prostate cancer-specific mortality. The ongoing Comparison Arm for ProtecT (CAP) cluster randomised controlled trial (RCT) evaluates prostate cancer screening effectiveness by comparing primary care centres allocated to a round of prostate specific antigen (PSA) testing (intervention) ...
متن کامل